Siemens Healthineers upgrades mid-term guidance

Germany-based Siemens Healthineers is now expecting revenue growth of 6-8 percent in the period 2023-2025, up from its prior 5-percent estimate. Morever, the projection for earnings per share in this period is also raised, going from 10 percent to 15 percent.

Photo: Daniel Karmann/AP/Ritzau Scanpix

Siemens Healthineers, which sells products and solutions for the prevention, diagnosing, treatment and monitoring of diseases, has upgraded its mid-term guidance, Bloomberg News reports ahead of the company's capital markets day, referring to a press release.

Following the news, Siemens Healthineers' stock price went up 3.5 percent, trading at EUR 62.52.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Sanofi reduces US insulin prices for the uninsured

While bills to introduce a price cap on insulin are being discussed in the US Senate, Sanofi has beaten them to the punch and reduced the price of insulin products for US diabetes patients without insurance.

Further reading

Related articles

Latest news

See all jobs